Manmeet Ahluwalia is an Oncology physician. ClinicalTrials.gov lists 14 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
57 Kent Rd
Howell, NJ 077312452
Telephone
732-367-1535Provider last certified this registry record 30 Apr 2026.
Clinical trials
- Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Sponsor: Baptist Health South Florida
- Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Sponsor: Baptist Health South Florida
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Sponsor: Baptist Health South Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
44.2%Erythropoiesis-stimulating Agent37.3%Darbepoetin alfa100%Part B, office-administered≥27 patientsIron, parenteral preparations6.8%Ferric derisomaltose100%Part B, office-administered≥31 patients+ 2 more classes in this area
Cancer & immunology
19.3%PD-1 inhibitor19.2%Pembrolizumab100%Part B, office-administered≥14 patientsAntimetabolite0%Hydroxyurea100%Part D<11 patientsMetabolism & gastrointestinal
18.5%Substance P/Neurokinin-1 Receptor Antagonist14.7%Aprepitant100%Part B, office-administered≥23 patientsSerotonin-3 Receptor Antagonist3.8%Ondansetron hydrochloride54%Palonosetron hcl44%Ondansetron Hcl2%Part D + Part B≥51 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”